Citations

Showing 10 of 108094 citations.

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis
Klamer, Brett , Brown, Paul D. , Cerhan, Jane H. , Anderson, S. Keith , Carrero, Xiomara W., Whitton, Anthony , Greenspoon, Jeffrey , Ashman, Jonathan B. , Bahary, Jean-Paul , Urbanic, James J., Barker, Fred G., Farace, Elana, Khuntia, Deepak , Buckner, Jan C. , Laack, Nadia N I, Palmer, Joshua D. , Ballman, Karla V. , Parney, Ian F. , Laack, Nadia N. , Hadjipanayis, Costas G. , Giannini, Caterina , Galanis, Evanthia , Roberge, David

Mayo Clinic

JAMA Oncology | October 20, 2022 | Volume: 8 | Issue: 12 | Pages: 1809

10.1001/jamaoncol.2022.5049 | PMID 36264568 Get It

Importance Long-term outcomes of radiotherapy are important in understanding the risks and benefits of therapies for patients with brain metastases. Objective To determine how the use of postoperative whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) is associated with quality of life (QOL), cognitive function, and intracranial tumor control in long-term survivors with 1 to 4 brain metastases. Design, Setting, and Participants This secondary analysis of a randomized phase 3 clinical trial included 48 institutions in the US and Canada. Adult patients with 1 resected brain metastases but limited to those with 1 to 4 brain metastasis were eligible. Unresected metastases were treated with SRS. Long-term survivors were defined as evaluable patients who lived longer than 1 year from randomization. Patients were recruited between July 2011 and December 2015, and data were first analyzed in February 2017. For the present study, intracranial tumor control, cognitive deterioration, QOL, and cognitive outcomes were measured in evaluable patients who were alive at 12 months from randomization and reanalyzed in June 2017. Interventions Stereotactic radiosurgery or WBRT. Main Outcomes and Measures Intracranial tumor control, toxic effects, cognitive deterioration, and QOL. Results Fifty-four patients (27 SRS arm, 27 WBRT arm; female to male ratio, 65% vs 35%) were included for analysis with a median follow-up of 23.8 months. Cognitive deterioration was less frequent with SRS (37%-60%) compared with WBRT (75%-91%) at all time points. More patients declined by 2 or more standard deviations (SDs) in 1 or more cognitive tests for WBRT compared with SRS at 3, 6, and 9 months (70% vs 22%, 46% vs 19%, and 50% vs 20%, respectively). A 2 SD decline in at least 2 cognitive tests was associated with worse 12-month QOL in emotional well-being, functional well-being, general, additional concerns, and total scores. Overall QOL and functional independence favored SRS alone for categorical change at all time points. Total intracranial control for SRS alone vs WBRT at 12 months was 40.7% vs 81.5% (difference, −40.7; 95% CI, −68.1% to −13.4%), respectively. Data were first analyzed in February 2017. Conclusions and Relevance The use of SRS alone compared with WBRT resulted in less cognitive deterioration among long-term survivors. The association of late cognitive deterioration with WBRT was clinically meaningful. A significant decline in cognition (2 SD) was associated with overall QOL. However, intracranial tumor control was improved with WBRT. This study provides detailed insight into cognitive function over time in this patient population. Trial Registration ClinicalTrials.gov Identifier: NCT01372774 ; ALLIANCE/CCTG: N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group)
Compressed Biceps Autograft Augmentation of Arthroscopic Rotator Cuff Repair
Tokish, John M. , Shaha, James S., Denard, Patrick J. , Mercuri, Jeremy , Colbath, Gregory, Denard, Patrick J

Mayo Clinic

Arthroscopy Techniques | October 20, 2022 | Volume: 11 | Issue: 11 | Pages: No page available

10.1016/j.eats.2022.08.011 | PMID 36457381 Get It

Abstract Rotator cuff repair failure rates continue to be a challenging problem. Various methods of biological and structural augmentation of the rotator cuff have been explored to improve tendon healing after repair. We describe a technique in which biceps tendon autograft is harvested after tenodesis. The biceps tendon is then compressed into a patch that is placed over the repaired rotator cuff tendon. Repurposing the portion of the tendon that is otherwise discarded offers several advantages over other augmentations that have been used, including the biological potential of live autograft tenocytes in the patch, lower cost, and no donor‐site morbidity. Technique Video video See video under supplementary data.
Adrenal venous sampling for lateralization of cortisol hypersecretion in patients with bilateral adrenal masses
Johnson, Paige , Thompson, Scott M. , Fleming, Chad J. , McKenzie, Travis J. , Cheville, John C. , Andrews, James C. , Johnson, Paige C , Adamo, Daniel, Adamo, Daniel A. , Bancos, Irina , Young, William F.

Mayo Clinic

Clinical Endocrinology | October 20, 2022 | Volume: 98 | Issue: 2 | Pages: 177-189

10.1111/cen.14833 | PMID 36263687 Get It

AbstractObjectiveThe objective of this study was to evaluate the role of adrenal venous sampling (AVS) in guiding the management of patients with corticotropin (ACTH)‐independent glucocorticoid secretory autonomy and bilateral adrenal masses.Design and PatientsA cohort with 25 patients underwent AVS and surgical management.MeasurementsCortisol was measured from the adrenal veins (AVs) and inferior vena cava (IVC). AV/IVC cortisol ratio and cortisol lateralization ratio (CLR) (dominant AV cortisol concentration divided by the nondominant AV cortisol concentration) were calculated. Posthoc receiver‐operating characteristic curves were generated to determine the specificity of revised AV/IVC cortisol ratio and CLR in differentiating unilateral from bilateral disease.ResultsPatients underwent unilateral (n = 21) or bilateral (n = 4) adrenalectomy. The mean AV/IVC cortisol ratio for unilateral adrenalectomy was 12.1 ± 9.6 (dominant) and 4.7 ± 3.8 (contralateral) with a mean CLR of 3.6 ± 3.5. The mean AV/IVC cortisol ratio for bilateral adrenalectomy was 7.5 ± 2.1, with a mean CLR of 1.1 ± 0.6. At a mean follow‐up of 22 months, one patient who underwent unilateral adrenalectomy for the predicted bilateral disease developed recurrent mild autonomous cortisol secretion. Posthoc analyses demonstrated a specificity of 95%–100% for unilateral disease with AV/IVC cortisol ratio >9 for one side, <2.0 for the opposite side and a CLR > 2.3. The specificity was 80%–90% for bilateral disease with AV/IVC cortisol ratio >5.1 bilaterally and a CLR < 1.1.ConclusionsAmong patients with bilateral adrenal masses and ACTH‐independent autonomous cortisol secretion, AVS can distinguish between unilateral and bilateral disease with high specificity and may guide surgical management.
The effect of burosumab on intact and C‐terminal FGF23 measurements
Ashrafzadeh‐Kian, Susan , Ito, Nobuaki , Sethna, Christine B. , Garg, Uttam, Katô, Hajime , Bornhorst, Joshua A. , Ashrafzadeh-Kian, Susan Louise , Srivastava, Tarak , Bornhorst, Joshua , Algeciras‐Schimnich, Alicia

Mayo Clinic

Clinical Endocrinology | October 20, 2022 | Volume: 99 | Issue: 2 | Pages: 152-157

10.1111/cen.14832 | PMID 36263608 Get It

AbstractObjectiveTo investigate the effect of CRYSVITA® (burosumab‐twza) on FGF23 measurements in an intact and a C‐terminal immunoassay.MethodsAn intact serum FGF23 (MedFrontier) and a C‐terminal plasma FGF23 assay (Immutopics) were used. Serum/plasma pools were spiked to span the burosumab therapeutic range (1.4–11.3 μg/ml) and FGF23 recovery was assessed. Patient serum and plasma samples obtained pre and post‐burosumab treatment were evaluated on both assays and compared with corresponding phosphorus measurementsResultsSpiking burosumab (1.4–11.3 μg/ml) into sample pools resulted in a dose‐dependent negative analytical interference on intact FGF23 measurements and no significant interference for C‐terminal FGF23 measurements. However, more than a 500‐fold median increase (post‐ vs. pre‐burosumab administration) in in vivo FGF23 concentrations were observed by both assays.ConclusionsTherapeutic concentrations of burosumab result in a negative analytical interference of the intact, but not the C‐terminal FGF23 immunoassay. Despite this in vitro analytical interference in the intact assay, relatively large elevations of both intact FGF23 and C‐terminal FGF23 measurements were observed in vivo following burosumab administration. Following burosumab administration, FGF23 measurements must be interpreted within the clinical context of the patient and other relevant biomarker results.SummaryThis article describes a negative analytical interference by burosumab in an intact FGF23 immunoassay. The recovery of C‐terminal FGF23 is not significantly affected by the presence of burosumab. In vivo, both assays demonstrate extreme FGF23 elevations in the presence of the drug. Furthermore, the measurement of FGF23 blocked by burosumab is not clinically useful regarding hypophosphataemia.
Is intestinal permeability increased in obesity? A review including the effects of dietary, pharmacological and surgical interventions on permeability and the microbiome
Camilleri, Michael

Mayo Clinic

Diabetes, Obesity and Metabolism | October 20, 2022 | Volume: 25 | Issue: 2 | Pages: 325-330

10.1111/dom.14899 | PMID 36263962 Get It

Genetic mutation profile in HER2 positive lobular breast cancer
Gaire, Suman , Joshi, Utsav , Shah, Anish , Yadav, Sumeet K, Budhathoki, Pravash , Yadav, Siddhartha

Mayo Clinic

International Journal of Cancer Care and Delivery | October 20, 2022 | Volume: 2 | Issue: Supplement 2 | Pages: No page available

10.53876/001c.38884 Get It

Polymicrobial Infections in the Immunocompromised Host: The COVID-19 Realm and Beyond
Higgins, Eibhlín, Gupta, Aanchal , Cummins, Nathan W.

Mayo Clinic

Medical Sciences | October 20, 2022 | Volume: 10 | Issue: 4 | Pages: 60

10.3390/medsci10040060 | PMID 36278530 Get It

Immunosuppression changes both susceptibility to and presentation of infection. Infection with one pathogen can also alter host response to a different, unrelated pathogen. These interactions have been seen across multiple infection domains where bacteria, viruses or fungi act synergistically with a deleterious impact on the host. This phenomenon has been well described with bacterial and fungal infections complicating influenza and is of particular interest in the context of the COVID-19 pandemic. Modulation of the immune system is a crucial part of successful solid organ and hematopoietic stem cell transplantation. Herein, we present three cases of polymicrobial infection in transplant recipients. These case examples highlight complex host–pathogen interactions and the resultant clinical syndromes.
A Participatory Framework for Plain Language Clinical Management Guideline Development
Francisco, Rita , Gomes, Catarina , Granjo, Pedro, Pascoal, Carlota , Brasil, Sandra , Neves, Alice Cristina Medeiros das, Krasnewich, Donna M., Lam, Christina , Jaeken, Jaak , Videira, Paula A. , Ferreira, Vanessa dos Reis , Gomes, Catarina , Pascoal, Carlota , Videira, Paula A , Alves, Susana, Neves, Alice, Santos, Inês, Miller, Andrea , Morava, Éva

Mayo Clinic

International Journal of Environmental Research and Public Health | October 19, 2022 | Volume: 19 | Issue: 20 | Pages: 13506

10.3390/ijerph192013506 | PMID 36294089 Get It

Background: Clinical management guidelines (CMGs) are decision support tools for patient care used by professionals, patients, and family caregivers. Since clinical experts develop numerous CMGs, their technical language hinders comprehension and access by nonmedical stakeholders. Additionally, the views of affected individuals and their families are often not incorporated into treatment guidelines. We developed an adequate methodology for addressing the needs and preferences of family and professional stakeholders regarding CMGs, a recently developed protocol for managing congenital disorders of glycosylation (CDG), a family of rare metabolic diseases. We used the CDG community and phosphomannomutase 2 (PMM2)-CDG CMGs as a pilot to test and implement our methodology. Results: We listened to 89 PMM2-CDG families and 35 professional stakeholders and quantified their CMG-related needs and preferences through an electronic questionnaire. Most families and professionals rated CMGs as relevant (86.5% and 94.3%, respectively), and valuable (84.3% and 94.3%, respectively) in CDG management. The most identified challenges were the lack of CMG awareness (50.6% of families) and the lack of plain language CMG (39.3% of professionals). Concordantly, among families, the most suggested solution was involving them in CMG development (55.1%), while professionals proposed adapting CMGs to include plain language (71.4%). Based on these results, a participatory framework built upon health literacy principles was created to improve CMG comprehension and accessibility. The outputs are six complementary CMG-related resources differentially adapted to the CDG community’s needs and preferences, with a plain language PMM2-CDG CMG as the primary outcome. Additionally, the participants established a distribution plan to ensure wider access to all resources. Conclusions: This empowering, people-centric methodology accelerates CMG development and accessibility to all stakeholders, ultimately improving the quality of life of individuals living with a specific condition and raising the possibility of application to other clinical guidelines.
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
Muñoz, Javier , Castillo, Jorge J. , Paludo, Jonas , Sarosiek, Shayna , Castillo, Jorge J , Munoz, Javier L , Paludo, Jonas

Mayo Clinic

Cells | October 19, 2022 | Volume: 11 | Issue: 20 | Pages: 3287

10.3390/cells11203287 | PMID 36291152 Get It

Waldenström macroglobulinemia (WM) is a rare form of non-Hodgkin B-cell lymphoma with a variable clinical presentation that can impact a patient’s quality of life by causing anemia, peripheral neuropathy, serum hyperviscosity, extramedullary disease, and other symptoms. There are several safe and effective treatment regimens for patients with WM, and the choice of therapy should be made in a personalized fashion considering the patient’s symptoms, comorbidities, and genomic profile. Bruton tyrosine kinase (BTK) inhibitors are a new option to treat patients with WM. Zanubrutinib is a next-generation covalent BTK inhibitor designed to have fewer off-target effects than previous BTK inhibitors. This review summarizes the pharmacokinetic and pharmacodynamic properties of zanubrutinib as well as safety and efficacy findings. Then, it explores the health economic and outcomes research associated with the costs of treating patients with WM and the reasons why zanubrutinib may be a more cost-effective treatment option compared with ibrutinib, a first-generation BTK inhibitor. Future directions for the treatment of WM focus on the use of zanubrutinib in combination therapy. Combinations based on effective ibrutinib or acalabrutinib treatments may be effectively applied with zanubrutinib given the similar mechanism of action for these BTK inhibitors. Combination therapies could also help prevent the development of disease resistance, minimize toxicity, and support treatment regimens of finite duration.
Resistance to Trastuzumab
Vivekanandhan, Sneha , Knutson, Keith L. , Knutson, Keith L.

Mayo Clinic

Cancers | October 19, 2022 | Volume: 14 | Issue: 20 | Pages: 5115

10.3390/cancers14205115 | PMID 36291900 Get It

One of the most impactful biologics for the treatment of breast cancer is the humanized monoclonal antibody, trastuzumab, which specifically recognizes the HER2/neu (HER2) protein encoded by the ERBB2 gene. Useful for both advanced and early breast cancers, trastuzumab has multiple mechanisms of action. Classical mechanisms attributed to trastuzumab action include cell cycle arrest, induction of apoptosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). Recent studies have identified the role of the adaptive immune system in the clinical actions of trastuzumab. Despite the multiple mechanisms of action, many patients demonstrate resistance, primary or adaptive. Newly identified molecular and cellular mechanisms of trastuzumab resistance include induction of immune suppression, vascular mimicry, generation of breast cancer stem cells, deregulation of long non-coding RNAs, and metabolic escape. These newly identified mechanisms of resistance are discussed in detail in this review, particularly considering how they may lead to the development of well-rationalized, patient-tailored combinations that improve patient survival.